Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A randomized, open-label, controlled, multicenter, global study on progression-free and overall survival in previously untreated patients with unresectable stage IIIC or stage IV melanoma with V600E BRAF mutation receiving RO5185426 or dacarbazine
vemurafenib
NO25026 (BRIM3)
NCT01006980
malignant melanoma of skin
Phase 3
 
January 2014

Powered by ideaPoint, Inc.